{"id":293544,"date":"2025-11-18T22:37:09","date_gmt":"2025-11-18T22:37:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/293544\/"},"modified":"2025-11-18T22:37:09","modified_gmt":"2025-11-18T22:37:09","slug":"morgans-thinks-this-asx-healthcare-stock-could-double","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/293544\/","title":{"rendered":"Morgans thinks this ASX healthcare stock could double!"},"content":{"rendered":"

\"Two<\/p>\n

Image source: Getty Images<\/p>\n

EBR Systems Inc. (ASX:EBR<\/a>) is a small-cap<\/a> ASX healthcare stock.\u00a0<\/p>\n

It is a clinical stage company that has developed its patented Wireless Stimulation Endocardial (WiSE<\/a>) technology. The technology is for the treatment of cardiac rhythm disease. Specifically, it aims to eliminate the need for cardiac pacing leads when delivering cardiac resynchronisation Therapy (CRT).\u00a0<\/p>\n

It’s worth noting that investors in clinical-stage companies should adopt a long-term focus on small-cap companies like this.\u00a0<\/p>\n

Meaningful returns often depend on multi-year clinical, regulatory, and commercial milestones that can progress slowly and unpredictably<\/a>.<\/p>\n

With that being said, the team at Morgans has identified EBR systems as an ASX healthcare stock with plenty to be optimistic about.\u00a0<\/p>\n

The broker has a buy recommendation and attractive price target on EBR systems shares.<\/p>\n

Positive feedback\u00a0 <\/p>\n

A note out of Morgans yesterday said feedback from the recently concluded Asia Pacific Heart Rhythm Society (APHRS) conference highlighted a meaningful shift in physician sentiment where confidence in conduction system pacing (CSP) for heart failure appears to be cooling following the PhysioSync-HF trial, reinforcing CRT’s position as the superior therapy.\u00a0<\/p>\n

We believe US physicians with early commercial WiSE experience are increasingly likely to focus on de novo applications, which may accelerate market expansion beyond previously untreatable CRT patients.\u00a0<\/p>\n

These developments support our view that WiSE remains uniquely positioned in the evolving pacing landscape, with strengthening clinical pull-through and expanding addressable markets.<\/p>\n

Overall, these trends reinforce that WiSE is well positioned in the shifting pacing landscape. Particularly with growing clinical demand and a widening market opportunity.<\/p>\n

Attractive price target for this ASX healthcare stock <\/p>\n

The team at Morgans has a buy rating on EBR systems shares with a price target of $2.86.\u00a0<\/p>\n

Based on yesterday’s closing share price of $1.07, this indicates an upside of more than 160%.\u00a0<\/p>\n

Morgans aren’t the only broker optimistic on this ASX healthcare stock.\u00a0<\/p>\n

In a report from Bell Potter<\/a> last week, the broker said EBR’s early commercial rollout is showing strong momentum.\u00a0\u00a0<\/p>\n

EBR reported a tripling in quarterly revenue to c.US$0.51m and Gross Profit to c.US$0.22m in 3Q25 as pre-reimbursement commercial activity picked up momentum.<\/p>\n

The broker also said a number of data points show an encouraging early trend in the commercialisation launch.<\/p>\n

For these reasons we believe consensus revenue estimates of c.US$15.7m in FY26 are low and expect upgrades to follow.<\/p>\n

The team at Bell Potter also has a recommendation on this ASX healthcare stock with a price target of $2.43.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Image source: Getty Images EBR Systems Inc. (ASX:EBR) is a small-cap ASX healthcare stock.\u00a0 It is a clinical…\n","protected":false},"author":2,"featured_media":109846,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,137,500],"class_list":{"0":"post-293544","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-au","9":"tag-australia","10":"tag-health","11":"tag-healthcare"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/293544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=293544"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/293544\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/109846"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=293544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=293544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=293544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}